Announcements Trials
Browse Landscape

Phase

Phase 2 46Phase 3 10Phase NA 6Phase 1 5Phase 4 2Phase 2/3 2Phase 1/2 2

Status

Unknown 6Completed 6Terminated 3Active not recruiting 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1CNS 1

Conditions

Neoplasms 2Recurrence 1NSCLC 1Glioma 1Gastrointestinal Neoplasms 1EGFR Mutation Positive Non-small Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Exercise 59Radiotherapy 49Blood Specimen Collection 45Radiosurgery 37Drug Therapy 35Standard of Care 32Surgical Procedures, Operative 30Magnetic Resonance Spectroscopy 26Laparoscopy 24Cisplatin 24Cyclophosphamide 23Control Groups 23Biopsy 23Acupuncture Therapy 23Magnetic Resonance Imaging 20Saline Solution 19Radiofrequency Ablation 19Endoscopic Mucosal Resection 19camrelizumab 16Surveys and Questionnaires 16Propofol 16Metformin 16Cytarabine 16anlotinib 15Preoperative Exercise 15Injections 15Fluorouracil 15Radiotherapy, Intensity-Modulated 14Neoadjuvant Therapy 14Early Intervention, Educational 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase NA × Unknown × Erlotinib Hydrochloride × Clear all
NCT02239952 2020-10-08

HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)

Amsterdam UMC, location VUmc

Phase NA Unknown
15 enrolled
CNS

Glioma, Neoplasms

NCT04007835 2019-07-05

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Guangdong Association of Clinical Trials

Phase NA Unknown
120 enrolled
Thoracic

NSCLC

NCT02015728 2016-12-15

SEED

Seattle Children's Hospital

Phase NA Unknown
20 enrolled

Neoplasms, Recurrence

NCT02013089 2016-08-30

GITIC

Sun Yat-sen University

Phase NA Unknown
50 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

NCT01776684 2013-01-28

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

Samsung Medical Center

Phase NA Unknown
200 enrolled
Thoracic

EGFR Mutation Positive Non-small Cell Lung Cancer

NCT00903292 2009-05-18

Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

National Cheng-Kung University Hospital

Phase NA Unknown
52 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡